Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia

Published:2020-11-04 Issue:2 Volume:27 Page:622-631
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Han Yoon-Chi,Kahler Jennifer^ORCID,Piché-Nicholas Nicole^ORCID,Hu Wenyue,Thibault Stephane^ORCID,Jiang Fan,Leal Mauricio^ORCID,Katragadda Madan,Maderna Andreas,Dushin Russell,Prashad Nadira,Charati Manoj B.,Clark Tracey,Tumey L. Nathan^ORCID,Tan Xingzhi,Giannakou Andreas,Rosfjord Edward^ORCID,Gerber Hans-Peter,Tchistiakova Lioudmila,Loganzo Frank^ORCID,O'Donnell Christopher J.^ORCID,Sapra Puja

Funder

Pfizer

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of inflammation-related cytokines and immune cells on bladder cancer：A mendelian-randomization study;2024-04-24

2. Association of Inflammation-Related Cytokines and Immune Cells on Bladder Cancer: A Mendelian-Randomization Study;2024

3. PROxAb Shuttle: A non-covalent plug-and-play platform for the rapid generation of tumor-targeting antibody-PROTAC conjugates;2023-09-29

4. The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions;Toxicology and Applied Pharmacology;2023-08

5. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1;Leukemia;2023-03-28